|
gptkbp:instanceOf
|
substance abuse
alkaloid
|
|
gptkbp:ATCCode
|
N07XX10
|
|
gptkbp:CASNumber
|
83-74-9
|
|
gptkbp:chemicalFormula
|
C20H26N2O
|
|
gptkbp:contraindication
|
heart disease
pregnancy
|
|
gptkbp:discoveredBy
|
1901
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:firstIsolatedFrom
|
gptkb:Dybowski_and_Landrin
|
|
gptkbp:foundIn
|
gptkb:Tabernanthe_iboga
|
|
gptkbp:halfLife
|
7.5 hours
|
|
gptkbp:hasSMILES
|
CN1CC2CC3C1C4=CC=CC=C4C2CC5C3N(C)C5
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ibogaine
|
|
gptkbp:IUPACName
|
gptkb:12-methoxyibogamine
|
|
gptkbp:legalStatus
|
gptkb:Schedule_I_(United_States)
illegal in France
prescription drug in New Zealand
|
|
gptkbp:mechanismOfAction
|
NMDA receptor antagonist
norepinephrine reuptake inhibitor
kappa-opioid receptor agonist
nicotinic acetylcholine receptor antagonist
sigma-2 receptor agonist
|
|
gptkbp:meltingPoint
|
152–153 °C
|
|
gptkbp:metabolism
|
gptkb:noribogaine
liver
|
|
gptkbp:molecularWeight
|
310.44 g/mol
|
|
gptkbp:not_approved_by
|
gptkb:FDA_(United_States)
EMA (European Union)
|
|
gptkbp:origin
|
gptkb:West_Africa
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL123
197060
170741
|
|
gptkbp:researched_for
|
gptkb:depression
PTSD
alcohol dependence
nicotine dependence
opioid addiction
stimulant addiction
|
|
gptkbp:riskFactor
|
death
seizures
QT prolongation
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
intravenous
|
|
gptkbp:sideEffect
|
gptkb:arrhythmia
ataxia
hallucinations
|
|
gptkbp:toxicity
|
can cause fatal cardiac arrhythmias
|
|
gptkbp:UNII
|
1U8C1UFJ3T
|
|
gptkbp:used_in
|
Bwiti religious ceremonies
|
|
gptkbp:usedFor
|
addiction treatment
psychedelic therapy
|
|
gptkbp:bfsParent
|
gptkb:Hallucinogenic_Plants
gptkb:Hallucinogens
|
|
gptkbp:bfsLayer
|
7
|